Positive data reported from phase III BRAVE-AA2 study of baricitinib in alopecia areata (AA)

RCT in 546 adults with ≥50% scalp hair loss and a current episode of severe AA lasting ≥6 months but not >8 years found 2 and 4mg doses of baricitinib met primary efficacy endpoint at week 36, demonstrating statistically significant improvement in scalp hair regrowth vs. placebo.

Source:

Biospace Inc.